Cat Vaccine Study Against Coronavirus Launches in New York

Applied DNA Sciences, Inc. announced on September 16, 2020, that it and a spin-out of Takis Biotech are expected to initiate a veterinary clinical trial of one of the Company’s five LineaDNA™ vaccine candidates upon approval of the clinical plan by the U.S. Department of Agriculture. The goal of this vaccine is to prevent infections from the SARS-CoV-2 coronavirus in companion felines (cats).

Launched in Brewster, N.Y., this study will evaluate (30) feline immune responses of the LineaDNA vaccine candidate, which will be injection 1x per month at 1mg/month for the first 3-months of the trial, with dosing administered intramuscularly. The primary endpoint is to determine evidence of antibody and T-cell response in the companion felines.

In addition to curbing feline SARS-CoV-2 infections, the vaccine may have a secondary benefit of preventing the transfer of the SARS-CoV-2 virus from cats to their human owners.